Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000781406 | SCV000919408 | uncertain significance | not specified | 2018-04-30 | criteria provided, single submitter | clinical testing | Variant summary: GALT c.313G>A (Asp105Asn) results in a non-conservative amino acid change located in the N-terminal of the Galactose-1-phosphate uridyl transferase (IPR005849) of the encoded protein sequence. Two of three in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 121412 control chromosomes (ExAC). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.313G>A in individuals affected with Galactosemia and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |